Share on StockTwits

Questcor Pharmaceuticals (NASDAQ:QCOR) has earned a consensus rating of “Hold” from the eleven ratings firms that are covering the stock, reports. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $84.50.

In other Questcor Pharmaceuticals news, Insider Michael H. Mulroy sold 10,000 shares of Questcor Pharmaceuticals stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.33, for a total value of $923,300.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on QCOR shares. Analysts at Oppenheimer downgraded shares of Questcor Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, July 25th. They now have a $86.00 price target on the stock. Analysts at Mizuho downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, May 19th. They now have a $92.00 price target on the stock.

Questcor Pharmaceuticals (NASDAQ:QCOR) traded up 1.63% during mid-day trading on Thursday, hitting $93.58. 168,594 shares of the company’s stock traded hands. Questcor Pharmaceuticals has a 1-year low of $47.71 and a 1-year high of $97.80. The stock’s 50-day moving average is $92.85 and its 200-day moving average is $81.06. The company has a market cap of $5.585 billion and a price-to-earnings ratio of 16.14.

Questcor Pharmaceuticals (NASDAQ:QCOR) last released its earnings data on Thursday, July 24th. The company reported $1.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.11. The company had revenue of $278.80 million for the quarter, compared to the consensus estimate of $261.02 million. During the same quarter in the previous year, the company posted $1.12 earnings per share. The company’s revenue for the quarter was up 38.5% on a year-over-year basis. Analysts expect that Questcor Pharmaceuticals will post $6.94 EPS for the current fiscal year.

Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.